OBI Pharma (ROCO:4174) Cyclically Adjusted Book per Share: NT$55.52 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4174 OBI Pharma Inc ROCO:4174
43 GF Score
Price NT$28.40
GF Value NT$138.61
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is OBI Pharma Cyclically Adjusted Book per Share?

OBI Pharma ROCO:4174 -1.90% 43 Cyclically Adjusted Book per Share is NT$55.52 as of Dec. 2025. GuruFocus rates ROCO:4174 with a GF Score™ of 43/100 and a GF Value™ of NT$138.61 (Possible Value Trap). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

OBI Pharma's adjusted book value per share for the three months ended in Dec. 2025 was NT$14.353. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$55.52 for the trailing ten years ended in Dec. 2025.

During the past 12 months, OBI Pharma's average Cyclically Adjusted Book Growth Rate was -12.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of OBI Pharma was -2.50% per year. The lowest was -2.50% per year. And the median was -2.50% per year.

As of today (2026-07-15), OBI Pharma's current stock price is NT$28.40. OBI Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was NT$55.52. OBI Pharma's Cyclically Adjusted PB Ratio of today is 0.51.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of OBI Pharma was 3.07. The lowest was 0.48. And the median was 1.97.


OBI Pharma  (ROCO:4174) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

OBI Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=28.40/55.52
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of OBI Pharma was 3.07. The lowest was 0.48. And the median was 1.97.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


OBI Pharma Cyclically Adjusted Book per Share Related Terms


OBI Pharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for OBI Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OBI Pharma Cyclically Adjusted Book per Share Chart

OBI Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 59.89 62.66 63.40 55.52

OBI Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.40 61.96 60.14 58.11 55.52

ROCO:4174 vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, OBI Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OBI Pharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where OBI Pharma's Cyclically Adjusted PB Ratio falls into.


ROCO:4174
43GF Score
OBI Pharma Inc ROCO:4174
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OBI Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, OBI Pharma's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=14.353/324.0540*324.0540
=14.353

Current CPI (Dec. 2025) = 324.0540.

OBI Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201603 75.396 238.132 102.600
201606 75.469 241.018 101.470
201609 72.463 241.428 97.263
201612 70.492 241.432 94.616
201703 66.029 243.801 87.764
201706 63.975 244.955 84.633
201709 60.920 246.819 79.983
201712 57.918 246.524 76.133
201803 57.962 249.554 75.266
201806 57.386 251.989 73.798
201809 53.240 252.439 68.344
201812 48.981 251.233 63.178
201903 47.088 254.202 60.027
201906 61.903 256.143 78.315
201909 58.469 256.759 73.793
201912 58.142 256.974 73.319
202003 50.309 258.115 63.161
202006 47.202 257.797 59.333
202009 43.400 260.280 54.034
202012 41.851 260.474 52.067
202103 39.935 264.877 48.857
202106 35.340 271.696 42.150
202109 32.186 274.310 38.023
202112 26.869 278.802 31.230
202203 48.758 287.504 54.957
202206 45.912 296.311 50.211
202209 44.826 296.808 48.941
202212 40.256 296.797 43.953
202303 38.506 301.836 41.340
202306 42.304 305.109 44.931
202309 37.522 307.789 39.505
202312 33.014 306.746 34.877
202403 28.598 312.332 29.671
202406 24.899 314.175 25.682
202409 20.473 315.301 21.041
202412 29.012 315.605 29.789
202503 25.146 319.799 25.481
202506 20.079 322.561 20.172
202509 16.629 324.800 16.591
202512 14.353 324.054 14.353

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of NT$55.52 mean?
OBI Pharma (ROCO:4174) has a Cyclically Adjusted Book per Share of NT$55.52 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on OBI Pharma and its competitors.
Is OBI Pharma's Cyclically Adjusted Book per Share too high?
OBI Pharma's current Cyclically Adjusted Book per Share is NT$55.52. Overall, OBI Pharma has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OBI Pharma's Cyclically Adjusted Book per Share compare to VRTX and REGN?
OBI Pharma's Cyclically Adjusted Book per Share of NT$55.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on OBI Pharma and its competitors. OBI Pharma's current Cyclically Adjusted Book per Share is NT$55.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OBI Pharma stock overvalued right now?
Based on GuruFocus' analysis, OBI Pharma (ROCO:4174) is currently considered Possible Value Trap. The stock's GF Value™ is NT$138.61, compared to a current price of NT$28.40 — trading 79.5% below its estimated fair value. The current Cyclically Adjusted Book per Share is NT$55.52. OBI Pharma's overall GF Score™ is 43/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For OBI Pharma (ROCO:4174), the current Cyclically Adjusted Book per Share is NT$55.52 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OBI Pharma (ROCO:4174) Overvalued in 2026?

Based on GuruFocus' analysis, OBI Pharma stock appears to be undervalued. The current stock price of NT$28.40 is trading 79.5% below its estimated GF Value™ of NT$138.61. GuruFocus considers OBI Pharma to be Possible Value Trap.

Key valuation signals for ROCO:4174:

  • Cyclically Adjusted Book per Share: NT$55.52
  • GF Value™: NT$138.61 vs. price of NT$28.40 (79.5% below fair value)
  • GF Score™: 43/100 with 9 warning signs

No single metric tells the full story. See the ROCO:4174 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OBI Pharma Business Description

Address Zhongxiao East Road, 6th Floor, No. 508, Section 7, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is engaged in the research and development of novel therapeutic agents and biologics for patients with unmet medical needs. The company has three reportable segments: the anti-cancer new drug segment, the botulinum toxin new drug segment, and the CDMO segment. Geographically, it generates the majority of its revenue from Taiwan.
43GF Score

Get the complete analysis for ROCO:4174

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$28.40
Price
NT$138.61
GF Value